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Abstract
Background: As a potent CD8
+ T cell activator, peptide vaccine has found its way in vaccine development against
intracellular infections and cancer, but not against leishmaniasis. The first step toward a peptide vaccine is epitope mapping
of different proteins according to the most frequent HLA types in a population.
Methods and Findings: Six Leishmania (L.) major-related candidate antigens (CPB,CPC,LmsTI-1,TSA,LeIF and LPG-3) were
screened for potential CD8
+ T cell activating 9-mer epitopes presented by HLA-A*0201 (the most frequent HLA-A allele).
Online software including SYFPEITHI, BIMAS, EpiJen, Rankpep, nHLApred, NetCTL and Multipred were used. Peptides were
selected only if predicted by almost all programs, according to their predictive scores. Pan-A2 presentation of selected
peptides was confirmed by NetMHCPan1.1. Selected peptides were pooled in four peptide groups and the immunogenicity
was evaluated by in vitro stimulation and intracellular cytokine assay of PBMCs from HLA-A2
+ individuals recovered from L.
major. HLA-A2
2 individuals recovered from L. major and HLA-A2
+ healthy donors were included as control groups.
Individual response of HLA-A2
+ recovered volunteers as percent of CD8
+/IFN-c
+ T cells after in vitro stimulation against
peptide pools II and IV was notably higher than that of HLA-A2
2 recovered individuals. Based on cutoff scores calculated
from the response of HLA-A2
2 recovered individuals, 31.6% and 13.3% of HLA-A2
+ recovered persons responded above
cutoff in pools II and IV, respectively. ELISpot and ELISA results confirmed flow cytometry analysis. The response of HLA-A2
2
recovered individuals against peptide pools I and III was detected similar and even higher than HLA-A2
+ recovered
individuals.
Conclusion: Using in silico prediction we demonstrated specific response to LmsTI-1 (pool II) and LPG-3- (pool IV) related
peptides specifically presented in HLA-A*0201 context. This is among the very few reports mapping L. major epitopes for
human HLA types. Studies like this will speed up polytope vaccine idea towards leishmaniasis.
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Introduction
Leishmaniasis is a parasitic disease found in tropical and
subtropical countries and also in southern Europe. It is caused by
infection with Leishmania parasites, which are spread by the bite of
infected sand flies. There are several different forms of
leishmaniasis in people; the most common are cutaneous
leishmaniasis (CL), which causes skin sores, and visceral
leishmaniasis (VL), which affects some of the internal organs of
the body (http://www.cdc.gov/NCIDOD/DPD/parasites/leish-
mania/). Although CL does not end in death, many problems are
faced due to long-lasting lesions, cosmetic problems, high expenses
of treatment, side effects of existing drugs and drug resistance.
Despite the huge number of publications on different vaccination
strategies, there is yet no protective vaccine in routine use for
humans. Current control relies on chemotherapy to alleviate the
disease [1–3] and on vector control to reduce transmission [4].
It has been a consensus for a long time that a Th1 dominant
response instead of Th2 promotes IFN-c production, which
activates macrophages to kill parasites via nitric oxide production
and induces lesion healing and control of the parasite burden [5–
9]. Based on this theory, different vaccination strategies have been
examined so far including leishmanization [10], killed parasites
[11], live attenuated parasites [12], subunit vaccines including
recombinant or native proteins of different stages of parasite life
cycle and DNA vaccines [13–18], dendritic cell-based vaccines
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genic parasite-based vaccines [23]. Although many of these
strategies have shown promising results in mice [24–27] and dogs
[28–30], none of them has entered human trials except for Leish-
F1 (a recombinant fusion protein of LmsTI-1, TSA and LeIF) with
reported phase I and II clinical trials [31,32].
On the other hand, CD8
+ T cells as a potent arm of adaptive
immunity have drawn attention in controlling leishmaniasis, since
growing evidence has proved their participation in immune
response against different Leishmania species studied in experimen-
tal models and human. IFN-c production by these cells diverts a
transient Th2 response at the very beginning to Th1 [33] and
modulates the IFN-c production by CD4
+ T cells late after
[34,35], which ends in disease control at primary infection of
C57BL/6 mice. Muller et al. also showed an elevated IFN-c
production at secondary infection of immune mice to L. major due
to CD8
+ T cells [36,37]. These responses are also associated with
the cure of CL in human [38,39]. A major concern about CD8
+ T
cell activation refers back to cytotoxic activity of these cells.
Despite cytokine production which is thoroughly analyzed [40],
the role of cytotoxic activity in protection is still under
investigation. Cytotoxic activity has been shown at the site of
infection [41] concomitant with killing of parasite at CL cases
[42,43], but Diffuse Cutaneous leishmaniasis and Muco-cutaneous
leishmaniasis stay at two extremities of cytotoxic activity; the
former is associated with exhausted cytotoxicity [44] and the later
is associated with exaggerated activity and destructive effects [45]
compared to CL cases.
Today, there are many reports about different Leishmania
antigens eliciting CD8
+ T cell responses such as P8 and gp46
[46], Kmp11 [47], CPB [48], nucleosomal histones [49], LmaCIN
[50], LmsTI-1 and TSA [51] and A2 [52]. The concept that CD8
+
T lymphocytes could be important in protection and long-lasting
resistance to infection has opened up a new strategy in Leishmania
vaccine design known as ‘‘Polytope Vaccine’’ [53]. This strategy is
a new hope in vaccine field against leishmaniasis for upcoming
future [54]. Polytope vaccines are mainly designed as DNA
constructs encompassing nucleotide sequence of multiple epitopes
in tandem. This strategy faces challenges such as best peptide
arrangement in tandem [55,56] or flanking sequences of each
peptide [57–59] to make the chance of being chopped into right
peptides. However, it possesses some extraordinary advantages
over other subunit vaccines, especially the ability to direct the
immune system towards multi-epitope CD8
+ T cell responses
[60,61].
The first step toward a polytope vaccine idea is the identification
of HLA class I-restricted epitopes that are naturally processed and
presented in the context of HLA class I and potentially activate
CD8
+ T cells. Since there are very few reported epitopes specific
for Leishmania major (the main cause of CL in Iran) proteins, we
took advantage of the potential of immunoinformatic tools to
screen for L. major-specific epitopes from six known proteins that
could be presented via HLA-A2 (the most prevalent HLA
supertype in Iranian population). Studies like this will help to
speed up polytope idea towards leishmaniasis, since more and
more epitopes are required to be included in a vaccine if pilot
studies prove this strategy protective against cutaneous leishman-
iasis.
Materials and Methods
Protein selection
Antigens selected for this study included: CPB, CPC, LmsTI-1,
TSA, LeIF and LPG-3. The full sequences of the proteins were
extracted from GeneDB data on L. major strain MHOM/IL/80/
Friedlin summarized in Table 1. These proteins are already
defined as candidate antigens and selected based on high
expression in amastigote stage and/or potential to stimulate
CD8
+ T cell responses.
SignalP (http://www.cbs.dtu.dk/services/SignalP) analysis con-
firms that CPB and CPC are secretory proteins, LPG-3 is a
membrane-associated protein and the other three proteins are
Author Summary
Leishmaniasis is currently a serious health as well as
economic problem in underdeveloped and developing
countries in Africa, Asia, the Near and Middle East, Central
and South America and the Mediterranean region.
Cutaneous leishmaniasis is highly endemic in Iran,
remarkably in Isfahan, Fars, Khorasan, Khozestan and
Kerman provinces. Since effective prevention is not
available and current curative therapy is expensive, often
poorly tolerated and not always effective, alternative
therapies including vaccination against leishmaniasis are
of priority to overcome the problem. Although Th1
dominant response is so far considered as a pre-requisite
for the immune system to overcome the infection, CD8
+ T
cell response could also be considered as a potent arm of
immune system fighting against intracellular Leishmania.
Polytope vaccine strategy may open up a new way in
vaccine design against leishmaniasis, since they act as a
potent tool to stimulate multi-CD8 T cell responses. Clearly
there is a substantial need to evaluate the promising
epitopes from different proteins of Leishmania parasite
species. Some new immunoinformatic tools are now
available to speed up this process, and we have shown
here that in silico prediction can effectively evaluate HLA
class I-restricted epitopes out of Leishmania proteins.
Table 1. L. major specific proteins used as candidate antigens for 9-mer epitope screening.
Abbreviations Names Accession number
a
CPB Cathepsin L-like Protease or Type I Cysteine Proteinase LmjF08.1080
CPC Cathepsin B-like Protease or Type III Cysteine Peptidase LmjF29.0820
LmsTI-1 L .major Stress Indussible Protein LmjF08.1110
TSA Thiol-Specific-Antioxidant LmjF15.1100
LeIF Elongation Initiation Factor 2 Alpha Subunit LmjF03.0980
LPG-3 Lipophosphoglycan Biosynthetic Protein LmjF29.0760
aThe full sequences of the proteins were extracted from GeneDB data of L. major strain MHOM/IL/80/Fredlin.
doi:10.1371/journal.pntd.0001295.t001
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software included the signal peptide sequence.
Peptide prediction
To map the promising epitopes from six known proteins of L.
major, we focused on HLA-A*0201 because it is the most prevalent
allele in white population and is the most extensively studied HLA
class I allele. Data from dbMHC (http://www.ncbi.nlm.nih.gov/
dbMHC) shows the frequency of this allele about 25% in south-
west Asia. Low-resolution molecular HLA typing in Iranian
population has also confirmed the high frequency of HLA-A2
alleles compared with other populations of the world [62]. We
focused on 9-mer long peptides since HLA class I binds 9-mers
more frequently than 8, 10 or 11-mer peptides. In the first step of
analysis, protein sequences were screened individually for best
binding epitopes with the most common online algorithms:
SYFPEITHI [63] and BIMAS [64]. The cutoff score was adjusted
above 20 for SYFPEITHI and 100 for BIMAS (with some
exceptions for BIMAS score if necessary). Peptides matching both
criteria were selected for a second step of analysis. For this, protein
sequences were analyzed with five different algorithms for HLA-
A*0201 including EpiJen [65], Rankpep [66], nHLApred [67],
NetCTL [68] and Multipred [69]. The accuracy of all prediction
algorithms was set above 80–85% based on the thresholds used
(Table 2). Selected peptides through this process were then
analyzed by NetMHCpan1.1 [70] to check for the possibility of
binding to different alleles of HLA-A2 supertype specified as HLA-
A*0202-A*0206 and A*0209 (Table 3). These alleles are the most
prevalent ones in South West Asian populations as recorded by
dbMHC. Peptides with 100% identity to mice or human proteins
were excluded from the selected list based on BLASTP analysis
and replaced with others passing the criteria of whole sieving
process if possible. Peptides were synthesized with more than 90%
purity by Biosynthesis Company (Lewisville, TX, USA). Lyoph-
ilized powder was dissolved in Dimethyl Sulphoxide (DMSO-
Sigma, Germany) and stored aliquoted at 280uC till use.
Study subjects
67 CL recovered individuals (28 men and 39 women ranging
from 8 to 78 years old (25.3616.8 years) were sampled from an
endemic area for cutaneous leishmaniasis (Chaheshk, Mashhad
suburbs, Khorasan province). The individuals had recovered from
4 months to 6 years ago (2.2261.4 years) and had apparent scars
(one or more) on their faces, hands and/or legs. All volunteers had
recovered after a course of standard glucantime therapy. 66
healthy donors with no obvious signs and symptoms of
leishmaniasis (60 men and 6 women) were also sampled from
blood donation volunteers at Tehran Blood Transfusion Center
ranging from 20 to 62 years old (40.4611.3 year). All volunteers
had donated blood more than once. 20 ml of blood was sampled
Table 2. Characteristics of in silico predicted L. major specific CD8
+ T cell 9-mer peptides restricted to HLA-A*0201 allele.
scores
Protein Position
a
Peptide
sequence SYFPEITHI BIMAS EpiJen
b RANKpep
c/Proteasome
d nHLAPred
e NetCTL
f Multipred
g
CBP 192–200 LMLQAFEWV 22 1617 + 72/2 1 1.255 MB
285–293 QLNHGVLLV 28 159 + 73/+ 1 1.055 MB
330–338 LLTGYPVSV 28 118 + 91/2 1 1.284 MB
CPC 281–289 FLGGHAVKL 27 98 + 73/+ 0.97 1.097 MB
18–26 LLATTVSGL 29 83 + 90/+ 1 1,137 MB
LmSTI-1 146–154 LLMLQPDYV 23 1179 + 68/+ 1 1.027 MB
445–453 ALQAYDEGL 24 10 + 63/+ 0.93 1.218 MB
31–39 QLDEQNSVL 22 14 + 64/+ 1 0.791 MB
170–178 YMEDQRFAL 21 108 + 72/+ 0.99 1,102 MB
TSA 158–166 RLLEAFQFV 24 11025 + 87/+ 0.99 1.374 MB
104–112 MLADKTKSI 25 73 + 92/+ 1 1.194 MB
LeIF 86–94 VLLEKATIL 26 225 + 86/+ 1 1.05 MB
317–325 KVLTLFAVE 22 149 + 81/+ 0.61 1.225 MB
152–160 VVWVKITQV 21 197 + 68/+ 2 0.934 MB
LPG-3 14–22 LLLLGSVTV 30 437 + 86/+ 1 1.023 MB
164–172 FLVGDRVRV 25 319 + 80/+ 1 1.191 MB
41–49 MLDILVNSL 28 33 + 76/+ 1 1.142 MB
655–663 MTAERVLEV 25 15 + 74/+ 1 1.181 HB
aAmino acid position as in the protein sequence.
bThreshold set on 5% (percent of whole protein peptides that should be tested).
cSpecific binding threshold set on 2% (percent of whole protein peptides that should be tested).
dProteasomal cleavage.
eCut off score set on 0.5 (Threshold of binding).
fThreshold for epitope selection set on .0.75 (Threshold of binding).
gPromiscuous epitope predicted as moderate or high binder.
doi:10.1371/journal.pntd.0001295.t002
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signing an informed consent. 1 ml blood was also separately
gathered in tubes containing 0.5 M EDTA (Merck, Germany) for
DNA extraction.
Ethics statement
The present study was approved by ethical committee of
Pasteur Institute of Iran. All human blood samples were taken
under supervision of internal medicine in both Tehran and
Chaheshk (Mashhad) centers. All patients had signed the consent
letter before sampling.
Peripheral Blood Mononuclear Cell isolation
Peripheral Blood Mononuclear Cell (PBMC) was isolated by
standard density gradient centrifugation protocol using Ficol-
Hypaque. Briefly, 20 ml blood sample was diluted 1:1 with sterile
PBS buffer and uploaded on Ficol-Hypaque 1077 (Sigma,
Germany) and centrifuged at room temperature for 40 min at
2200 rpm. Mononuclear layer was separated and washed with
sterile PBS. Cells were counted and cryo-preserved in heat-
inactivated Fetal Calf Serum (FCS)-10% DMSO until use.
HLA-A2 typing
DNA from all samples was extracted by GF-1 Nucleic Acid
Extraction Kit (Vivantis, Canada) according to the kit instructions.
HLA-A2 positive individuals were screened by PCR-Sequence
Specific Primer (PCR-SSP) method according to Bounce et al. with
some modifications [71]. One pair of specific primers (P296 and
P302) was used to detect HLA-A*0201-A*0217 alleles. One pair of
HLA-DRB1 specific primers (P63 and P64) was used as internal
control (Table 4). PCR reaction mixture contained: 16 PCR
buffer (Amplisens biotechnologies, Moscow), 200 mM of each
dNTP, 1.5 mM MgCl2, 0.04 u/ml Taq DNA polymerase (Ampli-
sens biotechnologies, Moscow), 100 ng DNA, 1 pmol/ml each
specific forward and reverse primers and 0.1 pmol/ml each
forward and reverse internal control primers. The PCR cycling
program consisted of 1 cycle of 94uC-4 min, 6 cycles of 94uC-
25 sec, 65uC-45 sec. and 72uC-45 sec, 20 cycles of 94uC-25 sec,
61uC-45 sec. and 72uC-45 sec and a final extension of 72uC-
2 min. The amplicon length was 489 bp and 796 bp for specific
and internal control, respectively. T2 cells (ATCC CRL-1992)
were used as PCR positive control. These cells are homozygout for
HLA-A*0201 allele.
HLA-A*0201 typing
To screen HLA-A*0201 positive individuals, we used Gatz et al.
nested PCR protocol [72] with minor modifications. For the first
step, one pair of specific primer for HLA-A2 alleles (AL#37,
AL#AW) and one pair for all other alleles except A2 (SG#A, and
SG#NA2) were used. One pair of b2-microglobuline specific
alleles (SG#b2ms2, and SG# b2ma3) was also used as internal
control. The amplicon length was 812 bp for A2-specific reaction,
612 bp for non-A2-specific reaction, and 350 bp for internal
control, respectively. For the second step, five sets of reactions
were used: AL#22/AL#Q (718 bp), AL#22/AL#BF (547 bp),
AL#22/AL#BG (542 bp), AL#V/AL#14 (543 bp) and AL#V/
AL# 3 (565 bp). The sequence of primers is shown in Table 4. All
PCR reactions contained, 16 PCR buffer, 200 mM each dNTP,
1.5 mM MgCl2, 0.04 u/ml Taq DNA polymerase,1.6 pmol/ml
each specific primer and 0.4 pmol/ml each internal control,
100 ng DNA at first PCR reaction and 1 ml from 1:5 diluted A2
PCR amplicon in the nested reaction. PCR cycling was set the
same as before for A2 typing. If a sample was positive at first step
(A2 positive), then the amplicon was transferred to the second step
Table 3. HLA-A2 super-type binding possibility of selected peptides predicted by NetMHCPan1.1.
HLA-A2 super-type
Peptide pool Protein Position A0201 A0202 A0203 A0204 A0205 A0206 A0209
Pool I CBP 192–200 SB* SB SB SB SB SB SB
285–293 WB** SB SB WB WB WB WB
330–338 SB SB SB SB SB SB SB
CPC 281–289 SB SB SB WB SB SB SB
1 8 – 2 6S BS BS BW B S BW B S B
Pool II LmSTI-1 146–154 SB SB SB SB SB SB SB
445–453 WB SB WB WB WB WB WB
3 1 – 3 9 -W B -----
170–178 SB SB SB WB SB SB SB
Pool III TSA 158–166 SB SB SB SB SB SB SB
104–112 SB SB SB WB SB SB SB
LeIF 86–94 WB WB SB WB WB WB WB
317–325 SB SB SB SB SB SB SB
152–160 WB WB WB WB - WB WB
Pool IV LPG-3 14–22 SB WB WB WB WB SB SB
164–172 SB SB SB WB SB SB SB
4 1 – 4 9 W BS B W BW BW BW BW B
655–663 WB SB SB WB WB SB WB
*strong binder (Strong binders have an IC50 less than 50 nM).
**weak binder (Weak binders have an IC50 more than 50 nM and less than 500 nM.
doi:10.1371/journal.pntd.0001295.t003
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if all five sets of reactions were positive, although other A2 alleles
may have also been present. If even one reaction was negative, the
sample was HLA-A*0201 negative but other HLA-A2 alleles were
present.
In vitro stimulation of memory CD8
+ T cells with
predicted peptides
In this study, we used PBMCs from CL recovered individuals
and healthy donors to assay the antigenicity of predicted peptides
by short-term T cell clone preparation in vitro. For this,
cryopreserved cells were thawed at standard condition. 2610
6
cells were suspended in 2 ml RPMI 1640 (Sigma, Germany)
supplemented with 10% human AB serum (Sigma, Germany), 1%
HEPES (Sigma, Germany), 2 mM L.Glutamine (Sigma, Ger-
many) and 0.1% Gentamicin (Sigma, Germany), dispensed in 24-
well culture plates (Orange Scientific, Switzerland) and incubated
overnight at 37uC and 5% CO2 for rest. After 24 hours, cells were
stimulated with peptide pools at 10 mg/ml/peptide and also
freeze/thawed antigens of L. major (10 mg/ml) as indicator of
previous disease. Recombinant human IL-2 (Sigma, Germany) at
10 ng/ml final concentration was added after 24 hours and every
3 days along the culture period. After 10 day culture cells were
washed and re-stimulated at 96-well round bottom culture plates
(Orange Scientific, Switzerland) with peptide pools at the same
peptide concentration and anti-CD49d/anti-CD28 antibodies (BD
biosciences) as co-stimulators at 1 mg/ml final concentration. Cells
were also stimulated with Phorbol Myristate Acetate (50 ng/ml)
(Sigma, Germany) and Ionomicin (500 ng/ml) (Sigma, Germany)
mixture as control for cell activity and IFN-c production. IFN-c
secretion was stopped by Berfeldin A (Sigma, Germany) at 20 mg/
ml final concentration. After an overnight culture, cells were
stained for surface markers (CD3 and CD8) and intracellular IFN-
c (all from BD biosciences) to be analyzed by flow cytometry. 1 ml
of all supernatants was stored for further ELISA assay, before re-
stimulation at day 10.
Intracellular cytokine staining (ICCS) of IFN-c producing
cells
We referred to standard plate based protocols with some
modifications [73,74]. Briefly, after overnight incubation at 96-
well round bottom culture plates, cells were pelleted, washed with
PBS, and stained with anti-CD3-PE-Cy5 conjugated and anti-
CD8-PE conjugated antibodies, for 30 min at 4uC. After complete
washing, cells were fixed and permeabilized with Cytofix-
Cytoperm buffer (BD biosciences) for 20 min at 4uC. After
washing with buffer containing saponin (BD Cytofix-Cytoperm kit,
BD biosciences), cells were stained with anti-IFN-c-FITC
conjugated antibody for 30 min at 4uC, then fixed in 1%
Paraformaldehyde (Electron Microscopy Sciences, USA) solution.
Freshly stained and fixed cells were analyzed with argon ion laser
equipped BD FACScalibur flow cytometer (BD biosciences, USA).
250,000 events were collected and analyzed by FlowJo 7.5.3
(TreeStar, USA) for percent of CD8
+/IFN-c
+ T cells in CD3
+
region gated out of lymphocyte region.
Enzyme Linked Immunosorbent Assay (ELISA) for
secreted IFN-c
Cytokine assay for IFN-c production was performed according
to Human IFN-c ELISA kit instructions (R&D Systems, DuoSet,
USA). After in vitro stimulation for 10 days, culture supernatants
were collected and freezed. At the time of ELISA experiment,
150 ml of each culture supernatant (each in duplicate) was used to
detect the specific IFN-c production at related supernatants with
kit instructions. IFN-c concentrations were intercepted on the
standard curve.
Enzyme Linked Immunospot Assay (ELISpot) for IFN-c
and IL-4 secreting cells
ELISpot assay was followed as instructions provided in IFN-c/
IL-4 ELISpot kit (Diaclone, France) after in vitro stimulation for 10
days. PBMC were plated in duplicate at a concentration of 5610
5
cell/well along with peptide pools at a final concentration of
Table 4. Sequence Specific Primers used in PCR reactions for typing HLA-A2 and sub typing HLA-A*0201 allele.
Primers specificity Primer Sequence Definition
HLA- A*0201-17 alleles P296 GTG GAT AGA GCA GGA GGG Forward specific primer
P302 CCA AGA GCG CAG GTC CTCT Reverse specific primer
P63 TGC CAA GTG GAG CAC CCA A Forward specific primer
P64 GCA TCT TGC TCT GTG CAG AT Reverse specific primer
AL#37 CCT CGT CCC CAG GCT CT Forward specific primer
HLA-A*0201 (1st PCR) AL#AW TGG CCC CTG GTA CCC GT Reverse specific primer
SG#A, TGT CCG CCG CGG TCC AA Forward specific primer
SG#NA2 CTC GCC CCC AGG CTC C Reverse specific primer
SG#b2ms2 CGA TAT TCC TCA GGT ACT C Forward specific primer
SG#b2ma3 CAC AAC TTT CAG CAG CTT AC Reverse specific primer
HLA-A*0201 (2nd PCR) Al #22 CAC TCC ATG AGG TAT TTC TT Forward specific primer
AL #Q CTC CAG GTA GGC TCT CAA Reverse specific primer
AL# BG CGT CGC AGC CAT ACA TCC Reverse specific primer
AL# BF CCC CAC GTC GCA GCC AT Reverse specific primer
Al# V GAG CCA CTC CAC GCA CGT Forward specific primer
AL #14 AGG CCC ACT CAC AGA CTC Reverse specific primer
AL#3 GAC GGG GAG ACA CGG AAA Reverse specific primer
doi:10.1371/journal.pntd.0001295.t004
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microscope (Nicon, Japan). Results were expressed as spot forming
cells (SFC)/10
6 PBMC. The sample was considered positive when
the spots in stimulated wells were above mean+2SD of control un-
stimulated wells of each sample.
Statistical analysis
Fischer’s exact test and non-parametrical Mann Whitney U tests
were used to evaluate the difference between groups. P value less
than 0.05 has been considered significant.
Results
In silico analysis of six known L. major proteins for
potential candidate peptides
Through immunoinformatic analysis, eighteen 9-mer peptides
were selected as HLA-A*0201 binders from six different proteins.
Proteins were analyzed for best binding epitopes individually. The
most important criteria were based on absolute scores from two
mostly used online algorithms: SYFPEITHI with the score of more
than 20 and BIMAS with the score of more than 100 (with some
exceptions for BIMAS score if necessary). This first step limited the
selected peptides from each protein matching both criteria to less
than six peptides. In the next step of analysis, the screened peptides
from the first step were more analyzed through five more
algorithms to see whether the selected peptides were amongst
high-ranked ones in each program. The prominent aspect of the
selected algorithms is that they rank the peptides predicted out of a
protein sequence according to absolute scores (or maximum
binding score in Rankpep) and specify peptides as binders or non-
binders based on a predetermined threshold. Peptides selected in
the first step were adopted only if they passed the threshold of at
least four algorithms of second step and sat at high rank peptide
positions according to thresholds set for 80–85% accuracy. Finally,
peptides selected through this sieving process were blasted with
human and mice proteome and peptides with 100% identity were
substituted if possible with others that had acceptable position
passing through the sieving process. Table 2 summarizes the
candidate epitopes characteristics. NetMHCPan1.1 algorithm
predicted the selected peptides as binders to at least one more
allele in the A2 supertype (Table 3). Peptides were pooled in four
different groups, 4–5 peptides each: peptide pool I included CPB
and CPC (5 peptides), peptide pool II included LmsTI-1 (4
peptides), peptide pool III included TSA and LeIF (5 peptides) and
peptide pool IV included LPG-3 (4 peptides).
HLA-A2 typing
Using a well designed PCR-SSP method, we were able to screen
26 and 22 A2 positive individuals out of 67 L. major recovered (38%)
and 66 healthy donors (33%), respectively. Of these, 19 HLA-A2
+
recovered individuals were included in the test group, 11 HLA-A2
2
recovered individuals were selected as control group to define the
specificity of in vitro evaluated peptides for HLA-A2 and 6 HLA-A2
+
healthydonorswere selected ascontrolgroupto definethespecificity
of in vitro evaluated peptides for L. major. 15 out of 19 HLA-A2
+
recovered individuals (78%) and 5 out of 6 healthy donors (83%)
were HLA-A*0201 positive, respectively. Figure 1 shows the PCR
amplicon of T2 cells, HLA-A2
+ and HLA-A2
2 samples.
Specific memory CD8
+ T cells are detectable in PBMC of
cutaneous leishmaniasis recovered individuals
To assay the antigenicity of predicted peptides in vitro,s h o r t -
term T cell clone preparation was used. Although short-term
culture stimulation next to peptide (6–12 hrs long) followed by
ICCS is introduced as a potent CD8
+ T cell detecting system
[74,75], we used an in vitro stimulation protocol before ICCS to
more sensitively detect the very low frequency response of the CL
recovered individuals that had recovered years ago. Individual
response of HLA-A2
+ recovered volunteers (represented by
percent of CD8
+/IFN-c
+ T cells) after in vitro stimulation against
peptide pools II (19 samples tested) was notably higher than that
of HLA-A2
2 recovered individuals (p value=0.03 by Mann
Whitney U test) and healthy donors (p value=0.036 by Mann
Whitney U test). In contrast, Individual response of HLA-A2
+
recovered volunteers against other peptide pools, I and III and IV
(15 samples tested each) were not statistically significant
compared to the response of HLA-A2
2 recovered individuals (p
value.0.05), but were significant against healthy control donors
(p value,0.05). HLA-A2
2 recovered individuals were included in
this study to show the specificity of response to HLA-A2 alleles.
HLA-A2
+ healthy donors were included to show the specificity of
response to L. major epitopes. No response was totally detected in
this latter control group against any peptide pool stimulation. We
used the mean+2S Do fC D 8
+/IFN-c
+ T cells in percent in HLA-
A2
2 individuals as the cutoff for categorizing individuals in both
HLA-A2
+ and HLA-A2
2 groups to responders and non-
responders and find the association between these two categories
(Figure 2). 6 out of 19 (31.6%) HLA-A2
+ recovered ones
responded above cutoff values (mean+2 SD=0.2) in peptide
pool II statistically significant by Fisher’s exact probability test (p
value=0.045). 2 out of 15 (13.3%) HLA-A2
+ recovered ones
responded notably higher than cutoff (mean+2 SD=0.42) in
peptide pool IV in comparison to HLA-A2
2 individuals
(Figure 2), but this was not statistically significant (p value.0.05).
In the next two peptide pools, the HLA-A2
2 recovered
individuals showed positive responses as high as HLA-A2
+
individuals (peptide pool III) or even higher (peptide pool I),
which renders the difference statistically not significant by
Fisher’s exact probability test (p value.0.05). However, this
recommends that the predicted peptides may act as promiscuous
epitopes, able to bind to a wider range of HLA alleles besides
HLA-A2, and this is noteworthy to be further studied. Figure 3
depicts the positive response in six HLA-A2
+ responders against
peptide pool II and the positive response of two HLA-A2
+
responders against peptide pool IV. Excitingly, all responders
were typed as HLA-A*0201 except one which was typed as HLA-
A*0202 or HLA-A*0203. This sample showed lower response
than most of the other responders who were HLA-A*0201
positive (Figure 3, Donor 4). The response of volunteers to L.
major lysate (freezed/thawed antigens of parasite) was potentially
Figure 1. HLA-A2 screening by one step PCR. One step PCR-SSP
method was used to screen for HLA-A2 positives among all samples
included (recovered individuals and healthy donors). Lane 1 shows
100 bp DNA ladder marker, lane 4 shows the PCR reaction of T2 cells as
positive control, lane 3, 5 and 6 is related to negative samples and lane
2 is related to a positive sample.
doi:10.1371/journal.pntd.0001295.g001
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disease to assure previous infection and is summarized in Figure 4.
As shown in this figure, the difference between HLA-A2
+
recovered individuals and HLA-A2
2 individuals is not significant
(p value=0.054, Mann-Whitney U test) but the difference
between HLA-A2
+ recovered individuals and healthy donors (p
value=0.0002, Mann-Whitney U test) and between HLA-A2
2
recovered individuals and healthy donors (p value=0.0007,
Mann-Whitney U test) is significant with p value,0.05. This
confirmed the previous infection in recovered individuals and no
infection in healthy donors.
To further confirm the ICCS results, peptide-specific IFN-c
producing T cells were enumerated via ELISpot assay. Although
ELISpot is often performed without any preceding in vitro
stimulation, we performed exactly the same as previous to make
the results comparable to ICCS. Cells from three HLA-A2
+
responders to peptide pool II and one HLA-A2
2 non-responder
individual were stimulated in vitro against peptide pool II (as
described in materials and methods). After 10 days, they were re-
stimulated next to relevant peptides in 96-well PVDF-bottomed
plates coated with anti-human IFN-c and anti-human IL-4
antibodies for 48 hrs. Figure 5 depicts the positive response of
one of the responders that had detectable amount of IFN-c
production against peptide pool II (101 SFC/10
6 PBMC in
stimulated wells vs. 60 SFC/10
6 PBMC in un-stimulated wells).
No IL-4 was detected in this sample. On the other hand, HLA-
A2
2 non-responder individual showed no detectable response.
(13 SFC/10
6 PBMC in stimulated wells vs. 42 SFC/10
6 PBMC in
un-stimulated wells). Even though the other two responders had
no detectable response in ELISpot, this could be explained by the
higher sensitivity of ICCS to ELISpot proposed by some other
researchers [76,77].
Secreted IFN-c from PBMCs of HLA-A2
+ recovered
individuals stimulated against peptide pool II and IV is
detectable by ELISA in culture supernatants
Since we had detected HLA-A2 specific positive responses in
peptide pool II and IV, we used an ELISA system (with a
sensitivity of 15 pg/ml) to check the cytokine release in the
supernatants of cells cultured next to these peptide groups. Culture
supernatants of peptide pools II and IV stimulated samples were
analyzed for IFN-c production on day 10 before re-stimulation. By
intercepting all OD data on a standard curve, IFN-c concentration
was calculated in non-stimulated wells as background and also
stimulated wells. Net production was subtraction result of
background (un-stimulated wells) from stimulated wells. As shown
in Figure 6, IFN-c production against peptide pool II stimulation
was significantly higher in HLA-A2
+ recovered individuals
compared to HLA-A2
2 recovered ones (p value=0.011, Mann
Whitney U test) and healthy donors (p value=0.031, Mann
Whitney U test). Although higher responses were detected in
peptide pool IV, the difference was not statistically significant. We
used the mean+2 SD of IFN-c concentration in HLA-A2
2
individuals as the cutoff for categorizing individuals in both HLA-
A2
+ and HLA-A2
2 groups to responders and non-responders and
find the association between these two categories. 8 out of 13
(61.5%) and 4 out of 12 (33%) HLA-A2
+ recovered individuals
had detectable cytokine production well above the cutoff scores.
Fisher’s exact probability test showed significant difference in
peptide pool II (p value=0.0063) but not in peptide pool IV.
Although ELISA never ascribes the cytokine production to a
specific cell type when whole PBMC is in use, but it is indicated
that 9-mer peptides as recall antigen are only able to induce the
IFN-c production from CD8
+ T cells. Therefore, totally these
Figure 2. Status of CD8
+/IFN-c
+ T cell response of recovered HLA-A2
+ individuals compared to HLA-A2
2 individuals. 6 out of 19
(31.6%) and 2 out of 15 (13.3%) HLA-A2
+ recovered individuals responded above cutoff value (horizontal bar in each plot defined as mean + 2SD
CD8
+/IFN-c
+ response in HLA-A2
2 controls) against peptide pools II and IV, respectively. Fischer’s exact probability test showed that the response in
peptide pool II is statistically significant.
doi:10.1371/journal.pntd.0001295.g002
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cytometry analysis. The response in peptide pool IV may need to
be further analyzed in a larger group of patients to statistically turn
significant, but couldn’t be neglected due to main purpose of this
part of the study which was to identify the peptides naturally
processed and presented after infection, among all predicted ones.
Discussion
CD8
+ T cells primed at Th1 milieu can participate in immune
response by IFN-c production to activate macrophages, by
cytotoxic activity via perforin/granzyme production and/or Fas-
Fas ligand interaction or both mechanisms to disrupt the parasite
host [78]. One of the most effective strategies to activate CD8
+ T
cell responses while avoiding whole parasite structure as in
leishmanization or deleterious sequences that can activate harmful
Th2 responses as in protein subunit vaccines is ‘‘Polytope
Vaccine’’ strategy. Multiple CD8
+ T cell activating epitopes could
be included in the vaccine construct to induce a multi-CD8
+ T cell
response [79,80].
There are very few reports about Leishmania specific CD8
+
epitope mapping. Therefore, to begin for the polytope strategy,
massive experiments need to be conducted to map the promising
epitopes from different proteins of Leishmania species. Controversy
still remains regarding the route of activation of CD8
+ T cells in
leishmaniasis, since Leishmania resides within parasitophorous
vacuoles of the macrophage and it is not clear how these cells
present Leishmania antigens to CD8
+ T cells through MHC class I
[78]. Part of the existing data suggests that only external or
Figure 4. The response of individual volunteers to L. major
lysate. Freezed/thawed antigens of L. major were used to stimulate the
PBMCs in culture as previous disease indicator. The responses of L.
major recovered individuals were potentially detected at CD4 level.
Each point represents response of each individual. Horizontal bars
represent the median value of CD4
+/IFN c
+ T cells in the related group.
Statistical analysis shows a significant difference between R.A2
+ (HLA-
A2
+ recovered individuals) and R.A2
2 (HLA-A2
2 recovered individuals)
groups with H.A2
+ individuals (HLA-A2
+ healthy donors) with p
value,0.05.
doi:10.1371/journal.pntd.0001295.g004
Figure 3. Flow cytometric analysis of IFN-c production in positive samples. Positive response of six HLA-A2
+ individuals against peptides of
pool II (A) and 2 HLA-A2
+ individuals against peptides of pool IV (B) is depicted versus un-stimulated control of each sample. Dot plots show CD8 vs.
IFN-c staining. Upper right squares define the CD8
+/IFN-c
+ region. Numbers represent the percentage of IFN-c producing CD3
+/CD8
+ T cells in the
lymphocyte gate.
doi:10.1371/journal.pntd.0001295.g003
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to be presented in the context of HLA class I molecules, which is a
prerequisite for CD8
+ T cell activation [81,82]. However,
Requena et al. have shown specific CD8
+ T cell responses against
nucleosomal histones which are non-secretory proteins [49]. This
makes all the proteins noteworthy to be evaluated for CD8
+ T cell
epitopes. We focused on proteins with reported CD8
+ T cell
response in literature and acceptable level of expression in
amastigote stage.
To speed up the mapping process, immunoinformatic tools are
now in access. Plenty of algorithms are available on World Wide
Web [83–85], but there is no consensus on the most appropriate
one to predict more true positive epitopes. Due to lack of a
consensus mapping protocol with immunoinformatic tools, we
based our prediction on Trost et al. theory that greater prediction
accuracy can be achieved by combining the predictions from
several algorithms rather than relying on just one [86]. So we
started the prediction with two quantitative matrix methods
most-commonly in use: SYFPEITHI and BIMAS. These
methods do not differentiate binders and non-binders and one
should practically evaluate the immunogenicity of about 10% of
top scored peptides of a protein to mark positives with 85%
accuracy [87]. This is simplified by choosing peptides with scores
higher than 20 and 100 for SYFPEITHI and BIMAS,
respectively. It is believed that peptides selected on these scores
are energetically best fitted to HLA peptide binding groove [88–
93]. It must be noted that BIMAS scores are sometimes
disappointing and do not catch up to ideal score. This is due
to an innate characteristic of the algorithm that considers each
amino acid’s effect on overall affinity by its own and regardless of
other amino acids in the peptide sequence [85]. For this reason
we did not expect BIMAS score to be ideal in some cases.
Although a protein may have more than 30 peptides scoring
above 20 at SYFPEITHI, these are restricted to very few
epitopes scoring above 100 at BIMAS. This was a limiting step
reducing peptides to be analyzed for each protein to less than 6.
Figure 5. Enumeration of peptide-specific IFN-c producing T cells stimulated against peptide pool II by ELISpot assay. ELISpot
analysis (upper row) of a negative responder (HLA-A2
2 recovered individual) (A) and a positive responder (HLA-A2
+ recovered individual) (B) against
peptide pool II stimulation is depicted compared to flow cytometric results (lower row) of the same samples. PMA/Ion stimulation (C) and culture
medium only (D) are used as positive and negative controls, respectively. (a and c are related to un-stimulated controls of each sample, b and d are
related to stimulated samples with peptide pool II). Dot plots show CD8 vs. IFN-c staining. Upper right squares in each plot define the CD8
+/IFN-c
+
region. Numbers represent the percentage of IFN-c producing CD3
+/CD8
+ T cells in the lymphocyte gate.
doi:10.1371/journal.pntd.0001295.g005
Figure 6. Detection of secreted IFN-c from PBMCs stimulated against peptide pool II and IV by ELISA in culture supernatants. IFN-c
production was measured in culture supernatants of HLA-A2
+ recovered individuals (R.A2
+), HLA-A2
2 recovered individuals (R.A2
2), and HLA-A2
+
healthy donors (H.A2
+) stimulated against peptide pools II and IV. Each point represents the net result of individual experiments. Horizontal bars
represent the median value of the IFN-c concentration in the related group. The response of R.A2
+ individuals was detected higher than that of R.A2
2
ones in peptide pools II and IV.
doi:10.1371/journal.pntd.0001295.g006
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with EpiJen, Rankpep, nHLApred, NetCTL and Multipred.
These models are trained on binder and non-binder data and
discriminate these two based on predetermined thresholds.
Peptides selected at the first step were further approved only if
passed the threshold of at least four algorithms at the second step
of analysis. It should be mentioned that we did not select the
peptides according to their ranks in these algorithms because it is
not a consensus yet that peptides with higher rank predicted by
different algorithms (within those top scores beyond thresholds of
binding) are absolutely binders [94]. Different algorithms propose
that the peptides with scores (either absolute or maximum binding)
above the thresholds (setting to 80–85% accuracy) are top-score
peptides and one should test them all to find a binder in vitro and
in vivo.
HLA molecules that present the epitopes to the T cells are
among the most polymorphic molecules in human populations, so
the vaccine composing epitopes must cover the population HLA
diversity. The concept of HLA supertypes helps to reduce the
number of epitopes needed for this purpose, since many HLA
alleles, although different in sequence, have common binding
specificities. They can bind a peptide with more or less identical
affinity and are clustered in a defined supertype as A2, A3 and so
on [95,96]. These so-called promiscuous T cell epitopes that bind
several alleles at a supertype or between different supertypes are
advantageous for maximal population coverage [97,98].
NetMHCpan1.1 specified that selected peptides were binders to
at least one more HLA-A2 supertype alleles.
All prediction algorithms used in this project are indirect
methods that predict HLA binding, though not all HLA binders
are T cell epitopes [99]. In silico analysis even with high sensitivity
and specificity is just a prediction. There are no consensus ways
to predict desirable peptides with 100% accuracy. This
necessitates in vitro and in vivo evaluations to confirm antigenicity
[100,101]. In vitro stimulation to recall memory CD8
+ T cells
from Leishmania-infected individuals and intracellular cytokine
assay for IFN-c producing cells confirmed that HLA-A2
+ CL
recovered individuals have developed specific response against
peptides from LmsTI-1 and LPG-3 during the active phase of
their disease. This is of paramount importance since it shows that
the peptides are real T cell epitopes naturally processed and
presented to immune system during Leishmania infection. It might
even have been better to screen CD8
+ T cell response in
asymptomatic (sub-clinical) individuals since these are naturally
resistant individuals who may have established stronger immune
responses against leishmanial antigens. This study also showed
that the prediction is almost reliable by the algorithm combina-
tion we used. Chentoufi et al. previously showed that a
combination of SYFPEITHI and BIMAS considering proteaso-
mal cleavage predicted by NetCHop, MHC pathway and
MAPPP accurately specifies three potent epitopes out of ten
predicted ones from one protein [102]. Although we have not
dissected the peptide pools to individual peptides responsible for
the positive response (because of a small lymphocyte source and
also difficulty to discriminate a positive response against an
individual peptide due to time elapsed after recovery (averagely
two years), obviously at least two peptides (one from each pool of
II and IV) are qualified out of the eighteen predicted ones. This
confirms that QM algorithms in combination with machine
learning methods and ANN in particular can confine the peptides
to a small group worthwhile to be focused on ex vivo. The results
of this study showed that the way we predicted peptides could
discriminate probably dominant epitopes out of candidate
proteins.
According to HLA–A*0201 typing results, 83% of HLA-A2
+
responders to pool II (5 out of 6) and both HLA-A2
+ responders to
pool IV are HLA-A*0201 positive. One of the responders to
peptide pool II, was HLA-A*0201 negative .This is consistent with
promiscuity that predicted peptides could be presented in HLA-A2
alleles other than HLA-A*0201, and needs to be further confirmed
in a larger population of HLA-A2 individuals bearing other HLA-
A2 alleles. 76% of HLA-A2
+ recovered non-responder individuals
to peptide pool II (10 out of 13) and 84% of non-responders to
peptide pool IV (11 out of 13) were HLA- A*0201 positive.
Although only 31.6% and 13.3% of CL recovered HLA-A2
+
individuals responded in Peptide pools II and IV, respectively, this
is expectable and in complete agreement with other studies
evaluating peptide immunogenicity by recall responses from
infected individuals [90]. It might be a question whether pooling
the peptides adversely affects the response of each individual
peptide, but this seems unlikely since we have detected response in
all peptide pools. Therefore, pooling peptides does not seem a
limiting factor [103,104] considering that all peptides are
predicted with almost equal affinity for HLA binding and with
same stimulatory concentration at cultures. Of course this remains
to be more elucidated in an in vivo assay with HLA-A2 transgenic
mice. Other factors could be responsible in this regard including:
1- individual TCR repertoire, 2- stimulation conditions in vitro
which was set up the same way for all samples (based on the
immune response potency in each individual, some samples may
need more rigorous in vitro stimulation), 3- the time elapsed after
recovery that is different between individuals and affects the
frequency of existing memory T cells at blood samples, 4- actual
protein expression and processing level and 5- the most important
of all, the HLA content of every individual. The HLA content may
direct the response toward non-A2 alleles that potentially present
other peptides than predicted ones during natural course of the
disease.
In this study, we also detected positive responses in HLA-A2
2
recovered individuals against other two protein groups (CPB,
CPC, LeIF and TSA), which are also among the best candidate
antigens for vaccine design. It might be questioned how peptides
bearing HLA-A2 super-motif binding specificities bind other
alleles of different supertypes. One possible explanation could be
the overlap between supertypes in terms of specificity that a
peptide binds alleles in other supertypes [96]. So it is noteworthy
to further analyze these peptides for their HLA restrictions.
This is a novel study recording L. major specific CD8
+ T cell
responses against peptides presented in the context of human
HLA. The only recent report refers back to Walden et al. that
mapped potential T cell epitopes from Kinetoplastid membrane
protein of L. major (Kmp-11) via classical mapping for different
human HLA class I alleles [47]. Gazzinelli et al. have studied CD8
+
T cell responses against L. donovani A2 specific MHC I binding
peptide determined by BIMAS and have demonstrated that A2-
specific T cell responses are responsible for reduced parasitism in
both liver and spleen of BALB/c mice immunized with A2 and
challenged with L. chagasi [52]. Instead of one protein at a time,
Laouini et al. and Dumonteil et al. started genome-wide screenings
for novel epitopes in separate labs. This approach is for certain
impossible via classical mapping. However, using a combination of
T cell epitope prediction tools (QMs and machine learning
methods); both groups have successfully validated epitopes in
BALB/c mice [94,105]. These studies have put forward novel
candidate antigens for vaccine development not previously
reported. The peptides selected in this study are highly conserved
among different species of Leishmania as L. tropica, L. donovani, L.
mexicana and L. braziliensis and even other kinetoplastids. This
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especially for visceral leishmaniasis, in which CD8
+ T cell
activation is a must. However, this should be considered with
percussions about other cases such as muco-cutaneous leishman-
iasis that progress through an uncontrolled immune response.
Today, in Silico prediction studies could be complemented easily
by testing the immunogenicity of the predicted epitopes in HLA
transgenic mice bearing human HLA molecules instead of their
own MHC class I molecules [106]. This is a shortcut through
peptide evaluation for human polytope vaccines and there is no
need to predict for mouse-specific peptides. Our next approach is
to design a DNA construct based on the peptides related to
LmsTI-1 and LPG-3 and even the peptides from CPB and CPC
proteins and immunize HLA-A2 transgenic mice bearing HLA-
A*0201 allele to follow the immune response against individual
peptides in vivo. We believe that in vivo stimulation will give better
responses than in vitro stimulation so we can clearly dissect the
individual peptides of each pool responsible for positive responses.
It is necessary to assess the cytotoxic activity of stimulated CD8
+ T
cell clones since these clones could act in an unpredictable way
when triggered at very beginning of the response, and may
undesirably lead to pathogenesis administered as a vaccine
regimen. It would be useful to challenge the immunized mice
with infectious L. major to check for the potency of this polytope
structure to protect the mice against infectious Leishmania parasite.
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